



(51) International Patent Classification:

C12Q 1/68 (2006.01) *C07K 14/72* (2006.01)
A61K 31/00 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:

PCT/US2013/052395

(22) International Filing Date:

26 July 2013 (26.07.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/676,842 27 July 2012 (27.07.2012) US
61/783,763 14 March 2013 (14.03.2013) US
61/829,123 30 May 2013 (30.05.2013) US

(71) Applicant: **ARAGON PHARMACEUTICALS, INC.**
[US/US]; 12780 E1 Camino Real, Suite #301, San Diego,
CA 92130 (US).

(72) Inventors: **JOSEPH, James, David**; 10242 Lone Bluff
Drive, San Diego, CA 92127 (US). **HAGER, Jeffrey**;
13381 Benchley Road, San Diego, CA 92130 (US).
SENSINTAFFAR, John, Lee; 12777 Casa Avenida, Po-
way, CA 92064 (US). **LU, Nhin**; 3635 Ash Street, Unit 4,
San Diego, CA 92126 (US). **QIAN, Jing**; 9456 Compass
Point Drive, South #8, San Diego, CA 92126 (US).
SMITH, Nicholas, D.; 1204 Beryl Street, San Diego, CA
92109 (US).

(74) Agents: **DEKLEVA, Thomas, W.** et al.; Woodcock
Washburn LLP, Cira Centre, 12th Floor, 2929 Arch Street,
Philadelphia, PA 19104-2891 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

[Continued on next page]

(54) Title: METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE TO ANDROGEN RECEPTOR THERAPY



(57) Abstract: Described herein are modified androgen receptor polypeptides that are resistant to inhibition by an androgen receptor inhibitor. Described herein are compositions, combinations, and kits containing the modified androgen receptor polypeptides and methods of using the modified androgen receptor polypeptides. Also described herein are methods of using the modified androgen receptor polypeptides as screening agents for the identification and design of third-generation androgen receptor modulators. Also described herein are third-generation androgen receptor modulators that inhibit the activity of the modified androgen receptor polypeptides. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions, including cancers, such as castration resistant prostate cancers, that are mediated or dependent upon androgen receptors.

WO 2014/018926 A1



Published:

— *with international search report (Art. 21(3))*